Edition:
United States

Biocon Ltd (BION.NS)

BION.NS on National Stock Exchange of India

991.50INR
5:17am EST
Change (% chg)

Rs-5.10 (-0.51%)
Prev Close
Rs996.60
Open
Rs992.55
Day's High
Rs1,005.00
Day's Low
Rs988.00
Volume
511,833
Avg. Vol
923,991
52-wk High
Rs1,051.75
52-wk Low
Rs431.00

BION.NS

Chart for BION.NS

About

Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed... (more)
No analyst recommendations are available for BION.NS.

Overall

No Ratios Available.

Financials

  BION.NS Industry Sector
P/E (TTM): -- 45.86 30.46
EPS (TTM): -- -- --
ROI: -- -1.27 14.82
ROE: -- -1.00 16.24

US STOCKS-Wall St set for flat open; Trump conference in focus

* Futures: Dow up 2 pts, S&P down 2 pts, Nasdaq up 0.75 pt (Adds details, comments, updates prices)

Jan 11 2017

BRIEF-U.S. FDA accepts BLA for Mylan and Biocon's proposed biosimilar trastuzumab

* U.S. FDA accepts biologics license application (BLA) for Mylan and Biocon's proposed biosimilar trastuzumab

Jan 11 2017

BRIEF-Biocon and Mylan announce U.S. FDA submission for proposed biosimilar Trastuzumab

* Biocon Ltd says Mylan and Biocon announce U.S. FDA submission for proposed biosimilar trastuzumab Source text - (http://bit.ly/2eA3Db3) Further company coverage:

Nov 08 2016

BRIEF-Mylan and Biocon announce regulatory submission for insulin glargine

* Mylan and Biocon announce regulatory submission for insulin glargine accepted for review by European Medicines Agency Source text for Eikon: Further company coverage:

Nov 03 2016

BRIEF-Biocon Ltd posts Sept-qtr consol profit

* Sept-quarter consol total comprehensive income 2.06 billion rupees versus loss of 150 million rupees

Oct 20 2016

BRIEF-Mylan, Biocon announce regulatory submission for proposed biosimilar trastuzumab

* Mylan and Biocon announce regulatory submission for proposed biosimilar trastuzumab accepted for review by European Medicines Agency Source text for Eikon: Further company coverage:

Aug 25 2016

BRIEF-Mylan and Biocon announce regulatory submission accepted for review by EMA

* Mylan and Biocon announce regulatory submission for proposed Biosimilar Pegfilgrastim accepted for review by European Medicines Agency Source text for Eikon: Further company coverage: (Bengaluru Newsroom; +1 646 223 8780)

Jul 21 2016

Earnings vs. Estimates

No consensus analysis data available.